Terapija muptiple skleroze – od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida (CROSBI ID 238158)
Prilog u časopisu | pregledni rad (stručni)
Podaci o odgovornosti
Rajić Džolić, Zrinka ; Šipicki, Sara ; Perković, Ivana
hrvatski
Terapija muptiple skleroze – od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
Multiple sclerosis is an autoimmune neurodegenerative disease, with inflammation and demyelination in the central nervous system, which results in diff erent neurological symptoms. The disease is usually diagnosed as a relapsing-remittent multiple sclerosis (85 %), which is characterized by acute attacks followed by recovery. Here we describe drugs used in the therapy/management of multiple sclerosis. In the acute phase new symptoms appear or the current neurological status worsens. The standard therapy consists of high doses of methylprednizolone, which is efficacious and usually leads to a quick recovery. Disease-modifying drugs are used to reduce the frequency of relapses and to slow the progression of disability. The classical first line drugs are interferon-b and glatiramer acetate. Other drugs include fingolimod, teriflunomid, dimethylfumarate, mitoxantron, natalizumab, alemtuzumab and daclizumab. Immunosupressive agents are also used in the therapy. Th e third class of drugs are used to alleviate the symptoms of the disease. Here we describe the benefi tial eff ects of cannabinoids in more detail.
multipla skleroza, kortikosteroidi, lijekovi koji mijenjaju tijek bolesti, monoklonsko protutijelo, kanabinoid
nije evidentirano
engleski
Therapy of multiple sclerosis – of conventional therapy and monoclonal antibodies to cannabinoids
nije evidentirano
multiple sclerosis, corticosteroids, disease modifying therapy, monoclonal antibody, cannabinoid
nije evidentirano